Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;39(2):e128-e130.
doi: 10.1111/jdv.20109. Epub 2024 Jun 10.

Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series

Yijian Zhu  1 , Zhengzhou Shi  1 , Zhongyi Xu  1 , Suqing Liu  1 , Jian Zhang  1 , Qianqian Wang  1 , Ye Liu  1 , Chengfeng Zhang  1 , Min Jiang  1 , Leihong Xiang  1
Affiliations

Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series

Yijian Zhu et al. J Eur Acad Dermatol Venereol. 2025 Feb.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621–648.
    1. Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther. 2023;13(3):729–749.
    1. Zhang L, Chen S, Kang Y, Wang X, Yan F, Jiang M, et al. Association of clinical markers with disease progression in patients with vitiligo from China. JAMA Dermatol. 2020;156(3):288–295.
    1. Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol. 2016;174(6):1318–1326.
    1. Su X, Luo R, Ruan S, Zhong Q, Zhuang Z, Xiao Z, et al. Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo. J Am Acad Dermatol. 2023;89(6):1257–1259.

LinkOut - more resources